Designer Babies: CRISPR Ethics, Safety & Regulatory Landscape

"Designer baby" refers to genetic selection or modification of embryos for non-medical traits (intelligence, appearance, athletic ability). Current technology (CRISPR-Cas9) makes this theoretically possible but ethically and scientifically fraught.

Technical Capabilities (2024)

  • CRISPR-Cas9: Targeted genome editing; used in research embryos (not implanted).
  • Base/Prime editing: Fewer off-target effects; still experimental.
  • Preimplantation Genetic Testing (PGT): Selects embryos for chromosomes (PGT-A), monogenic diseases (PGT-M), polygenic scores (PGT-P – controversial).

Safety Concerns

ConcernDetails
Off-target editsUnintended cuts/mutations elsewhere in genome; improved but not eliminated by high-fidelity Cas9, prime editing.
MosaicismEditing after 1-cell stage → some cells edited, some not; unpredictable phenotype.
Large deletions / chromosomal rearrangementsChromothripsis-like events at target site.
Long-term unknownsNo human data beyond birth; epigenetic, developmental, transgenerational effects unknown.
Incomplete penetrance / pleiotropyEditing one gene affects multiple traits (e.g., CCR5 Δ32 → HIV resistance but ↑ West Nile severity).

Ethical Issues

  • Consent: Embryo cannot consent; parents decide for future person.
  • Equity: Access limited to wealthy → genetic caste system ("Gattaca" scenario).
  • Disability rights: Selection against traits devalues lives of people with those conditions.
  • Human dignity: Commodification of children; instrumentalization.
  • Slippery slope: Therapy → enhancement → eugenics.

Regulatory Status (Global)

  • WHO (2021): Global registry for human genome editing; moratorium on clinical germline editing.
  • US: FDA cannot review germline editing INDs (Congressional rider); NIH doesn't fund. State laws vary.
  • EU: Convention on Human Rights and Biomedicine (Oviedo) prohibits germline modification.
  • China: 2019 regulations: prison for He Jiankui; strict oversight now.
  • UK: HFEA licenses mitochondrial replacement (3-parent baby); nuclear germline editing prohibited.

Therapeutic vs. Enhancement Distinction

  • Therapeutic: Correct pathogenic variant (e.g., HBB for sickle cell) – widely supported.
  • Enhancement: Augment traits beyond species-typical – consensus: not permissible.
  • Boundary is blurry (e.g., PCSK9 editing for low cholesterol?).

Consensus

International academies (NAS, Royal Society, WHO): Heritable human genome editing should not proceed until safety, efficacy, oversight, and societal consensus are established. PGT-M for serious monogenic disease is accepted; PGT-P and germline editing are not.

Pregnancy & Health - Related Articles